Annals of Hematology最新文献

{"title":"Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.","authors":"Manon Garcia, Carolyne Croizier, Grégory Lazarian, Anne Quinquenel, Thomas Tassin, Céline Bourgne, Olivier Tournilhac, Jacques-Olivier Bay, Marc G Berger, Andréi Tchirkov, Lauren Véronèse, Romain Guièze","doi":"10.1007/s00277-025-06200-9","DOIUrl":"10.1007/s00277-025-06200-9","url":null,"abstract":"<p><p>The advent of BTK inhibitors has been transformative in the management of patients with chronic lymphocytic leukemia or other B-cell lymphoproliferative disorders. However, emergence of BTK or PLCG2 mutations lead to resistance to these compounds and are now a growing concern in clinical practice. Assessing BTK mutations is now becoming a priority to guide the therapeutic decision at further relapse. To this end, targeted next-generation sequencing (NGS) is a valid tool, but lack of sensitivity and the required time for delivering results remain major challenges. Digital PCR could be more sensitive but is also limited by the number of mutations that can be screened. We here overcame these challenges by multiplexing digital PCR (mdPCR) in three assays that can cover 96% of ibrutinib-resistant cases. We investigated a cohort of 28 patients progressing on ibrutinib and for whom NGS revealed BTK mutations (C481S, C481F and C481R) and/or PLCG2 R665W mutation. Overall, 49 mutations were detected by NGS and 68 by mdPCR. We found mdPCR to bemore sensitive than NGS, particularly at low allelic frequencies, making it more suitable for the detection and quantification of small mutated clones. Thus, mdPCR offers high sensitivity, is expected to be more rapid and cost-effective than NGS in detecting resistance mutations to improve the therapeutic choice at relapse after exposure to BTK inhibitors.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2889-2895"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143027777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic role of interim PET-CT demonstrating partial metabolic response in diffuse large B-Cell lymphoma: a retrospective study.","authors":"Jinjie Gao, Shuozi Liu, Meixin Zhao, Hua Zhang, Hongmei Jing","doi":"10.1007/s00277-025-06368-0","DOIUrl":"10.1007/s00277-025-06368-0","url":null,"abstract":"<p><strong>Objective: </strong>Interim ¹⁸F-FDG PET/CT (iPET/CT) imaging demonstrates potential in assessing the early therapeutic response in lymphoma. Nevertheless, the prognostic significance of interim PET-CT in diffuse large B-cell lymphoma (DLBCL) remains controversial. This study aimed to evaluate whether semi-quantitative PET/CT metabolic parameters and other metrics could enhance the prognostic value of interim PET/CT in DLBCL patients exhibiting partial metabolic remission (PMR).</p><p><strong>Methods: </strong>A retrospective analysis was performed from January 2018 to December 2023, focusing on patients with DLBCL who achieved PMR on interim PET-CT. Patient demographics, clinical characteristics, and semi-quantitative PET/CT metabolic parameters were extracted from the medical records. Multivariate analyses were conducted to identify the risk factors associated with failure to achieve complete metabolic remission (CMR) at the end of treatment (EOT). Receiver operating characteristic (ROC) curve analysis was employed to determine the optimal cut-off values for continuous predictive variables. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods, and risk factors were evaluated using Cox regression models.</p><p><strong>Results: </strong>In a cohort consisting of 80 newly diagnosed DLBCL cases that exhibited PMR on interim PET scans, 50 cases ultimately achieved CMR, while the remaining 30 cases still had positive PET findings at EOT. Analysis revealed that the interim lesion-to-liver maximum standardized uptake value ratio (RLL) and bone marrow involvement were independent prognostic factors for positive PET-CT outcomes at EOT. Notably, an interim RLL threshold greater than 1.66 emerged as a reliable predictor with a sensitivity of 73.3% and a specificity of 72.0%. Additionally, the International Prognostic Index (IPI) and interim RLL were identified as independent prognostic indicators for both progression-free survival (PFS) and overall survival (OS).</p><p><strong>Conclusion: </strong>Our study revealed that within the cohort of DLBCL patients exhibiting PMR on interim PET scans, an interim RLL greater than 1.66 and bone marrow involvement emerged as independent risk factors for positive PET results at the end of treatment. Additionally, the IPI and interim RLL were identified as independent prognostic markers for both progression-free survival and overall survival. The integration of clinical characteristics with semi-quantitative PET/CT parameters has the potential to enhance the prognostic role of interim PET/CT exhibiting PMR in DLBCL cases.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2777-2786"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?","authors":"Katherine J Taylor, Susanne Singer, Saskia Langemeijer, Richard J Kelly, Louise Arnold, Jens Panse, Christopher J Patriquin, Jun-Ichi Nishimura, Maria Piggin, Pascale O Burmester","doi":"10.1007/s00277-025-06377-z","DOIUrl":"10.1007/s00277-025-06377-z","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3073-3075"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety analysis of China's first 10% IVIg (RonsenGlob) therapy in treating adult ITP.","authors":"Lijun Fang, Ting Sun, Hu Zhou, Guitao Jie, Jiaping Fu, Enqin Yang, Zeping Zhou, Ligen Liu, Jingyu Zhang, Shenxian Qian, Yun Chen, Ling Liu, Jian Gu, Fanliang Kong, Ruibin Huang, Yunfei Chen, Lei Zhang","doi":"10.1007/s00277-025-06391-1","DOIUrl":"10.1007/s00277-025-06391-1","url":null,"abstract":"<p><p>A prospective, single-arm, open-label Phase III clinical trial was conducted across multiple centers in China from April 27, 2020, to June 15, 2021, to assess the efficacy and safety of 10% intravenous immunoglobulin (IVIg) in treating adult immune thrombocytopenic purpura (ITP). Within 7 days of treatment initiation, the 10% IVIg group exhibited an overall response rate of 87.0%, with 32 patients (46.4%) achieving complete response and 28 patients (40.6%) demonstrating partial response, comparable to the 5% IVIg group. Notably, the median time to achieve a platelet count (PLT) of 50 × 10⁹/L was significantly shorter for the 10% IVIg group at 2 days (IQR: 2-3) versus 3 days (IQR: 3-5) for the 5% IVIg group. Additionally, the 10% IVIg group reached a PLT of 100 × 10⁹/L in 3 days (IQR: 3-4), compared to 5 days (IQR: 4-6) for the 5% IVIg group. Post-treatment bleeding scores significantly decreased, and no significant adverse reactions were reported. This inaugural study highlights the efficacy and safety of 10% IVIg in the urgent management of adult ITP, positioning it as a rapid therapeutic option.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2643-2651"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL.","authors":"Yuhong Ren, Hui Tan, Jingli Zhuang, Luya Cheng, Ling Yuan, Lili Ji, Yang Ke, Xuejiao Zhang, Zhixiang Cheng, Jing Li, Peng Liu","doi":"10.1007/s00277-025-06412-z","DOIUrl":"10.1007/s00277-025-06412-z","url":null,"abstract":"<p><p>First-line treatment balancing efficacy and safety is urgently needed for frail and elderly diffuse large B-cell lymphoma (DLBCL) patients. We designed a triplet chemo-light regimen, Pola-ZR, in previously untreated frail and elderly DLBCL patients to assess the efficacy and safety in a prospective DLBCL cohort (NCT06203652). Polatuzumab vedotin was given 1.8 mg/KG intravenously on day 1, zanubrutinib 160 mg twice a day orally from day 1 to day 21, and rituximab 375 mg/m² intravenously on day 1. Twenty-one days were a cycle. If assessed complete response (CR) after 6 cycles, patients would receive zanubrutinib alone for another 6 cycles. PET/CT or contrast-enhanced CT scan was scheduled every 3 cycles. The primary end point was overall response rate (ORR) after 6 cycles. Twenty-four patients were enrolled from 01 Apr 2023 to 20 Dec 2023. Median age was 73. Sixteen (66.7%) patients had an international prognostic index score of 3 to 5. After a median follow-up of 10.2 months, the CR rate and ORR after 6 cycles was 83% and 83%. Non-responders had high total metabolic tumour volume. Lung infection was the major safety concern. PJP prophylaxis was recommended. Pola-ZR regimen showed rapid and deep response with manageable safety profiles in both GCB and non-GCB subtypes.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2823-2830"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimising survivorship post-BMT: healthcare professionals' perceptions of long-term care.","authors":"Gemma McErlean, Christine Ashley, Anisha Pradhan, Vanessa Yenson, Ian Kerridge, Elizabeth Halcomb","doi":"10.1007/s00277-025-06398-8","DOIUrl":"10.1007/s00277-025-06398-8","url":null,"abstract":"<p><p>Survivors who have received a blood or marrow transplant (BMT) require life-long follow-up care and support, however evidence-based assessments of long-term models of care are scarce. This qualitative descriptive study explored the perspectives of blood and marrow transplant (BMT) specialist nurses and physicians, and General Practitioners (GPs) regarding the long-term management and follow-up care of BMT survivors. Semi-structured online interviews were conducted with thirteen purposefully selected BMT Physicians (n = 4), Advanced Practice Nurses (APNs) (n = 6) and GPs (n = 3), experienced in providing long-term care to BMT survivors. Data were analysed using thematic analysis. Both specialist and community-based practitioners identified deficiencies in models of care delivery and in the organisation of long-term care for BMT survivors, particularly in relation to communication, transition and personalisation of care. Two themes were identified that explored (1) Efficiency and quality of current care provision for BMT survivors and (2) Characteristics of optimal care. All participants recognised the need for flexible, patient-centred models of shared care that bring together hospital and community-based healthcare professionals in providing optimal care to BMT survivors. The growing population of survivors of BMT requires an urgent re-evaluation of healthcare models to address their complex long-term care needs. This will require a well-trained primary care-based workforce supported by collaborative relationships with specialist centres and easy access to essential information. Current approaches to post-BMT care that limit provision of care to specialist BMT services are unsustainable, inefficient, and do not support the transition of patients from tertiary to community healthcare services.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2927-2935"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of type 2A von Willebrand disease with compound heterozygous mutation.","authors":"Li-Jing Wang, Qi Gao, Bo Pang, Tao Wu, Xuyang Zhang, Hansheng Fang, Haidan Chen, Huili Cai","doi":"10.1007/s00277-025-06363-5","DOIUrl":"10.1007/s00277-025-06363-5","url":null,"abstract":"<p><p>von Willebrand disease (VWD) is defined by a quantitative or qualitative deficiency of von Willebrand factor, which impairs platelet adhesion and aggregation. Here we describe a rare case of type 2A VWD with compound heterozygous mutation. A 27-year-old girl presented with oral bleeding for two days after dental surgery. A systemic physical examination turned up unremarkable. Type 2 von Willebrand disease was confirmed by laboratory tests. Further genetic investigation revealed the existence of compound mutations of VWF (von Willebrand factor) gene, inherited separately from her parents. Interestingly, her mother presented decreased VWF antigen and activity, but that was not found in her father.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3053-3057"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials.","authors":"Himil Mahadevia, Ben Ponvilawan, Anuj Shrestha","doi":"10.1007/s00277-025-06373-3","DOIUrl":"10.1007/s00277-025-06373-3","url":null,"abstract":"<p><p>Bruton tyrosine kinase inhibitors (BTKi) are utilized in the front-line setting as well as for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). However, there are some uncertainties regarding the risk of infections, especially pneumonia, from different BTKi with varied immunomodulatory effects on the innate and adaptive immune system. The newer second-generation BTKi, acalabrutinib and zanubrutinib, have reduced off-target effects compared to ibrutinib. We identified clinical trials from MEDLINE, Embase, and CENTRAL databases from the inception to 30 June 2023 and the number of cases with any grade and grade ≥ 3 pneumonia, pneumocystis pneumonia (PJP), and other fungal pneumonia, along with the total number of patients in the arms with BTKi monotherapy were extracted. The meta-analysis was performed using the inverse variance method and the random-effects model. After two rounds of review, 18 clinical trials containing 20 arms of BTKi monotherapy were eligible for the meta-analysis. The pooled incidences of any grade and grade ≥ 3 pneumonia in patients with CLL on BTKi therapy were 13% and 8%, respectively. There were no differences in the incidences of any grade (p = 0.61) or grade ≥ 3 pneumonia (p = 0.30) among patients treated with different BTKi. However, the pooled incidences of any grade and grade ≥ 3 pneumonia were greater in R/R CLL patients compared to those who were treatment-naïve (15% vs 7%, p < 0.01 and 10% vs 5%, p = 0.04, respectively). The pooled incidences of PJP and other fungal pneumonia were 1% (I² = 10%) and 1% (I² = 0%), respectively. Our study showed no significant differences in the incidence of pneumonia of any grade or grade ≥ 3 among patients treated with second-generation BTKi or first-generation BTKi. The risk of pneumonia may not be a factor in choosing among BTKi. Of note, the incidence of pneumonia was higher in R/R CLL patients on BTKi therapy when compared to treatment-naïve CLL. Fungal pneumonia, including PJP, is uncommon in CLL, and the subgroup analyses were not able to distinguish any differences among different BTKi.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2605-2616"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.","authors":"Ulrich Dührsen, Gabriele Prange-Krex, Regina Moeller, Harald Held, Gerhard Heil, Andreas Schwarzer, Stefan Mahlmann, Ariane Dienst, Matthias Sandmann, Georg Maschmeyer, Jochen Schütte, Dennis Hahn, Michael Heike, Michael Nonnemacher, Christine Hanoun, Andreas Hüttmann","doi":"10.1007/s00277-025-06402-1","DOIUrl":"10.1007/s00277-025-06402-1","url":null,"abstract":"<p><p>When different therapies provide similar cure rates, health-related quality of life (HRQoL) may become crucial for the choice of treatment. In the Positron Emission Tomography-guided Therapy of Aggressive non-Hodgkin Lymphomas (PETAL) trial, we compared six cycles of R-CHOP with or without two extra doses of rituximab in prognostically favorable interim PET (iPET)-negative patients, while eight cycles of R-CHOP were compared with two R-CHOP cycles followed by six cycles of a more intensive protocol in prognostically unfavorable iPET-positive patients. As reported previously, treatment intensification did not improve outcome. HRQoL was assessed using the EORTC QLQ-C30 questionnaire. Pretreatment questionnaires were obtained from 558 out of the 862 participants (64.7%). Pretreatment HRQoL was significantly worse than in the general population. It was associated with age, gender, B symptoms, International Prognostic Index (IPI) and total metabolic tumor volume (TMTV). Physical and cognitive functioning predicted survival independent of IPI or TMTV. During treatment, some domains remained stable (e.g., cognitive functioning, nausea/vomiting), while others improved (e.g., emotional functioning, pain) or deteriorated (e.g., physical functioning, role functioning, fatigue). At the end of treatment, HRQoL was better in patients with controlled disease than in patients with progressive disease and better for iPET-negative patients than for iPET-positive patients. During follow-up, all HRQoL domains returned to levels similar to those reported for the general population. Differences between randomized treatment arms were not observed. The longitudinal data need to be interpreted with caution, because decreasing participation resulted in a selection of patients with increasingly good outcomes. ClinicalTrials.gov no. NCT00554164 (registered 11/5/2007).</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2831-2845"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GPVI-dependent functional competence of buffy coat platelet concentrates (PCs) versus PRP-derived PCs: insights into the effects of biomechanical forces during platelet preparation.","authors":"Ehteramolsadat Hosseini, Pezhman Beshkar, Farshad Heydari, Mehran Ghasemzadeh","doi":"10.1007/s00277-025-06376-0","DOIUrl":"10.1007/s00277-025-06376-0","url":null,"abstract":"<p><p>Platelet isolation is a decisive stage in the preparation of platelet concentrate (PC), which may affect functional competence of platelets during storage and post-transfusion. Now considering GPVI as a vulnerable receptor that is mainly affected by shear stress and redox state, this study was conducted for the first time to compare preparation methods of Buffy Coat (BC)- and Platelet-Rich Plasma (PRP)-PCs in terms of GPVI-related phenotypic and functional status. BC- and PRP-PCs were subjected to flow cytometry to analyze GPVI expression and intra-platelet ROS generation. Soluble GPVI were determined by ELISA. Platelet aggregation response to collagen and its adhesion to the collagen matrix were examined by aggregometry and fluorescence microscope, respectively. All the parameters were analyzed on days 0, 1, 3, and 5 of storage. Stored-dependent ROS generation showed significantly higher levels in PRP-PCs compared to BC-PCs on days 1 and 3 of storage. GPVI expression decreased in both products, with BC-PCs showing higher levels on 1 and 3 days of storage. However, with a similar trend, PRP-PCs showed higher levels of shedding, which was significant on day 3. Adhesion/spreading to the collagen matrix also decreased during storage, with higher declines observed in PRP-PCs. Platelet aggregation showed the same pattern with significantly lower PRP-PCs responses to collagen than BC-PCs on the third and fifth days of storage. During platelet storage, GPVI-dependent platelet functional capacity in BC-PCs was better preserved than PRP-PCs, suggesting the priority of BC-PCs method for platelet preparation. In this regard, adopting methods such as platelet isolation and storage in optimal additive solutions, especially those containing ROS scavengers, may help maintain the integrity of GPVI in PRP products. However, further studies, particularly using animal models of thrombus formation, are needed to determine whether the enhanced GPVI function in BC-PCs compared with PRP-PCs can translate into superior efficacy after blood transfusion.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"2973-2988"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}